Uncategorized
Treat-and-extend therapy with Eylea for AMD improves vision, reduces injections over 2 years
LAS VEGAS — Two-year results of the ATLAS study showed visual and anatomic improvements in eyes with neovascular age-related macular degeneration treated with a treat-and-extend program using Eylea. “The treat-and-extend program has never been validated with aflibercept [Eylea, Regeneron] to date, and given the molecular differences of anti-VEGF drugs and the potential greater durability effect for aflibercept, my colleagues and I designed and conducted the ATLAS study,“ Carl D. Regillo, MD, FACS, said at the American Academy of Ophthalmology annual meeting.